Immunochemotherapy Before Surgery Cuts Recurrence Risk in Esophageal Cancer, Meta-Analysis Finds

For patients with locally advanced esophageal squamous cell carcinoma, the treatment given before surgery may shape not just whether the tumor shrinks, but where the cancer returns. A new meta-analysis published in BMC Cancer suggests that neoadjuvant chemoimmunotherapy, a regimen that pairs standard chemotherapy with immune checkpoint inhibitors, is associated with fewer overall recurrences after radical esophagectomy than the long-standing standard of neoadjuvant chemoradiotherapy. The finding, drawn from twenty comparative studies conducted in China, arrives at a moment when oncologists worldwide are debating whether radiation should remain part of the preoperative playbook for this aggressive disease, or whether drugs that unleash the immune system can do the job with less toxicity.

Esophageal squamous cell carcinoma is the dominant histological subtype of esophageal cancer in China and much of Asia, and it remains one of the most lethal malignancies anywhere. Even after neoadjuvant treatment and technically complete surgery, a substantial fraction of patients relapse, and the pattern of that relapse, whether it reappears near the tumor bed and regional lymph nodes or erupts in distant organs such as the liver, lung, or bone, carries profound prognostic weight. Distant metastasis after esophagectomy is notoriously difficult to salvage, which is why researchers have increasingly focused on systemic strategies that might suppress micrometastatic disease before it takes hold.

The meta-analysis, led by Yingding Ruan, Wenjun Cao, and colleagues at The First People’s Hospital of Jiande and Dalian University’s affiliated Zhongshan Hospital, systematically searched PubMed/MEDLINE, Embase, Web of Science Core Collection, Scopus, and the Cochrane Library through May 1, 2026. Eligible studies enrolled patients with resectable or potentially resectable locally advanced disease who received either neoadjuvant chemoimmunotherapy or neoadjuvant chemoradiotherapy followed by radical esophagectomy. Of the twenty included studies, nineteen were retrospective observational cohorts and only one was a randomized phase 2 trial, a detail that threads a caution through every conclusion the authors draw. Five studies contributed data on overall recurrence, and six studies each informed the analyses of locoregional and distant recurrence.

The headline results are statistically coherent but biologically nuanced. Neoadjuvant chemoimmunotherapy was associated with a roughly one-third reduction in overall recurrence, with a pooled risk ratio of 0.68 (95% confidence interval 0.49 to 0.95; P = 0.03). When the investigators separated recurrence by anatomical territory, the signal concentrated in the distant compartment: distant recurrence or metastasis showed a risk ratio of 0.62 (95% CI 0.43 to 0.89; P = 0.009), favoring the immunotherapy-containing approach. Locoregional recurrence, by contrast, was essentially indistinguishable between the two strategies, with a risk ratio of 1.02 (95% CI 0.67 to 1.55; P = 0.92).

That pattern makes biological sense. Chemoradiotherapy is, by design, an intensely locoregional intervention: radiation is delivered to the primary tumor and its nodal basin, sterilizing local disease but leaving distant micrometastases to the mercy of systemic chemotherapy alone. Immune checkpoint inhibitors, typically antibodies against PD-1 or its ligand PD-L1, act systemically, reactivating exhausted T cells that can patrol the bloodstream and hunt tumor cells seeded far from the esophagus. The meta-analysis’s finding that the advantage of chemoimmunotherapy lies precisely in the distant compartment aligns with this mechanistic logic and mirrors what has been observed in other tumor types where immunotherapy shifted the failure pattern from local to systemic control.

Yet the authors were unusually candid about the fragility of their findings, and this honesty is arguably the study’s most important contribution. In post hoc sensitivity analyses that excluded studies with marked imbalance in follow-up duration between treatment arms, the locoregional estimate remained nonsignificant (risk ratio 0.87, 95% CI 0.66 to 1.15), but the distant-recurrence signal was attenuated and lost statistical significance, with a risk ratio of 0.65 (95% CI 0.36 to 1.17). Follow-up asymmetry is a subtle and insidious bias in comparative oncology studies: if patients receiving one therapy are tracked substantially longer, they have more calendar time in which to relapse, and pooled event counts become treacherous to compare. That the key distant-recurrence result dissolved under this scrutiny means the strongest-looking finding in the analysis cannot yet be treated as settled evidence.

The survival analyses tell a similarly two-sided story. Ten studies contributed data on overall survival, which favored neoadjuvant chemoimmunotherapy with a hazard ratio of 0.67 (95% CI 0.48 to 0.93; P = 0.02), though the heterogeneity across studies was high, quantified by an I-squared of 77%. Eight studies provided disease-free or recurrence-free survival data, where the pooled hazard ratio of 0.82 (95% CI 0.59 to 1.13; P = 0.21) did not reach significance, again with substantial heterogeneity (I-squared = 74%). In meta-analytic terms, an I-squared above 75% indicates that the variation among studies exceeds what chance alone would explain, suggesting that differences in chemotherapy backbone, checkpoint inhibitor choice, radiation dose and technique, surgical approach, and patient selection are driving results in ways that a single pooled estimate cannot capture.

The predominance of retrospective evidence compounds these interpretive challenges. Retrospective cohorts are vulnerable to selection bias, since clinicians may preferentially assign fitter patients or those with favorable tumor biology to newer regimens, and techniques such as propensity score matching or inverse probability of treatment weighting, which some included studies used, can mitigate but never fully eliminate confounding. The authors assessed methodological quality using tools appropriate to the study designs, including the Newcastle-Ottawa Scale for observational studies, the ROBINS-I framework for non-randomized interventions, and the revised Cochrane risk-of-bias tool for the single randomized trial. Their stated conclusion is deliberately restrained: the findings do not establish therapeutic superiority and should be interpreted cautiously given the risk of bias and heterogeneity involved.

Why does this matter clinically? Neoadjuvant chemoradiotherapy has anchored the treatment of locally advanced esophageal cancer since the CROSS trial era, and its efficacy and safety profile are well mapped. But radiation adds cost, logistical burden, and toxicities, and some trials in adenocarcinoma histology have questioned whether omitting it sacrifices little. Neoadjuvant chemoimmunotherapy regimens, combining taxane-plus-platinum or fluorouracil-based chemotherapy with agents like PD-1 blockers, have generated striking pathological complete response rates in early trials, and the present meta-analysis now offers the first focused synthesis of how those responses translate into relapse behavior after esophagectomy. If the reduced overall recurrence risk proves real in randomized settings, patients could gain durable systemic control while avoiding a course of thoracic radiation, a meaningful shift in the treatment paradigm for squamous cell carcinoma of the esophagus.

What happens next is clear even if the authors do not spell it out: the field needs adequately powered randomized trials comparing these neoadjuvant strategies head-to-head, with equalized follow-up, blinded central review of recurrence events, and recurrence patterns reported in standardized anatomical categories. Emerging biomarkers such as circulating tumor DNA and minimal residual disease assays may eventually identify which patients truly need radiation on top of systemic therapy. Until such data mature, the meta-analysis stands as a provocative signal rather than a practice-changing verdict: chemoimmunotherapy before surgery appears to bend the recurrence curve for esophageal squamous cell carcinoma, plausibly by extending immune surveillance beyond the radiated field, but the evidence base, drawn almost entirely from China and dominated by retrospective designs, still demands the rigor of prospective confirmation before the old standard yields the throne.

Subject of Research: Recurrence patterns after neoadjuvant chemoimmunotherapy versus chemoradiotherapy in esophageal squamous cell carcinoma

Article Title: Locoregional and distant recurrence after neoadjuvant chemoimmunotherapy versus chemoradiotherapy in esophageal squamous cell carcinoma: a focused meta-analysis

Article References: Ruan, Y., Cao, W., Long, C., Li, C., & Han, J. (2026). Locoregional and distant recurrence after neoadjuvant chemoimmunotherapy versus chemoradiotherapy in esophageal squamous cell carcinoma: a focused meta-analysis. BMC Cancer. https://doi.org/10.1186/s12885-026-16944-w

Image Credits: AI Generated

DOI: 10.1186/s12885-026-16944-w

Keywords: esophageal squamous cell carcinoma, neoadjuvant chemoimmunotherapy, neoadjuvant chemoradiotherapy, recurrence, meta-analysis, immune checkpoint inhibitors, esophagectomy, distant metastasis, disease-free survival, overall survival, oncology, systematic review